BioSpace News Archive

ReGrasp Bionic Glove, a medical device designed to help patients speed hand rehabilitation following a stroke or injury, is now available in the United States for patients to use at home or in a clinical setting.

AbbVie today announced positive topline results from U-ENDURE, its Phase 3 maintenance study evaluating upadacitinib in adult patients with moderate to severe Crohn’s disease who had an inadequate response or were intolerant to a conventional or biologic therapy.

Evolus, Inc. announced that members of its management team will be participating in the H.C. Wainwright Global Investment Conference.

Ceapro Inc. (TSX-V: CZO; OTCQX:CRPOF) (“Ceapro” or the “Company”), announced today that results from a collaborative project with University of Alberta researchers have been accepted for publication in the Journal of CO2 Utilization in an article titled, “Drying of sodium alginate using Pressurized Gas eXpanded (PGX) liquid technology,” authored by Liu Z, Couto R., Seifried B, Yépez B, Moquin P and Temelli F.

Acera Surgical, Inc. announced that Michael Finegan is joining the company as CEO, effective immediately.

Exact Sciences Corp. announced the American Urological Association updated their guidelines to include genomic assays, such as the Oncotype DX Genomic Prostate Score® test, when treating men with localized prostate cancer.

ArisGlobal, the global market leader in drug safety solutions worldwide, and Boehringer Ingelheim, a leading research-driven biopharmaceutical company, today announced the acquisition of Boehringer Ingelheim’s digital innovation, BRASS, by ArisGlobal.

Cleveland Diagnostics, Inc. announced that its prostate cancer test, IsoPSA, has been added to the National Comprehensive Cancer Network Guidelines for Prostate Cancer Early Detection.

Horizon Therapeutics plc announced that Dara Mann, vice president, marketing, ophthalmology, has been named a 2022 Healthcare Businesswomen’s Association Rising Star.

Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today presented updates to its two lead programs at TIDES USA 2022: Oligonucleotide & Peptide Therapeutics Conference.